Myocardial Expression of PD-L1 as a Marker of Poor Prognosis in Immune Checkpoint Inhibitor-Associated Myocarditis.

JACC CardioOncol · 2026 · PMC13133651 · PMID 42017567

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

did not reach statistical significanceP = 0.051so close (0.05 < p ≤ 0.1)

The PD-L1 + area also tended to be greater in the MACE group than in the non-MACE group, although the difference did not reach statistical significance (6.44% [Q1-Q3: 2.71%-12.04%] vs 0.10% [Q1-Q3: 0.09%-0.25%], P = 0.051).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.